Keywords: Mylan, Crestor, Canada, Cholesterol lowerer, AstraZeneca, Roattapharm, M&A
Mylan gets OK for generic Crestor in Canada; Rottapharm deal looks dead
Article | 18 March 2012
The Canadian subsidiary of US generic drugmaker Mylan (Nasdaq: MYL) has received approval from Health Canada for Mylan-Rosuvastatin Calcium Tablets, 5 ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- AstraZeneca plans to move three cancer drug candidates into Ph III
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Merck Serono Ph III trial of L-BLP25 fails endpoint in NSCLC
